📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Biotheryx

1.1 - Company Overview

Biotheryx Logo

Biotheryx

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of clinical-stage protein degrader therapies, including the PRODEGY platform for targeted protein degradation; PHM molecular glues that use the body’s protein disposal system to selectively degrade disease-causing proteins; BTX-A51, an oral multi-kinase inhibitor for relapsed/refractory AML and high-risk MDS; and a pipeline of first-in-class molecular glue and bifunctional degraders for oncology and inflammatory disorders.

Products and services

  • PRODEGY Platform: A proprietary drug discovery engine that architects targeted protein degradation, utilizing components and tools for drug design to develop degraders against disease-causing proteins
  • PHM® Molecular Glues: Small-molecule modulators that regulate protein equilibrium by harnessing the body's protein disposal system to selectively degrade disease-causing proteins
  • BTX-A51: An oral multi-kinase inhibitor targeting leukemic stem cells and super-enhancer targets, intended for relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Biotheryx

Anokion Logo

Anokion

HQ: Switzerland Website
  • Description: Provider of antigen-specific immune tolerance solutions, including an engineered-protein platform for targeted autoimmune therapy without broad immunosuppression; liver-targeting technology to modulate inflammatory responses in antigen-mediated autoimmune diseases; antigen-specific vaccines to prevent reactions to self-antigens; and clinical research services to develop and test new therapies, reducing therapeutic protein immunogenicity.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Anokion company profile →
Flame Biosciences Logo

Flame Biosciences

HQ: United States Website
  • Description: Provider of clinical-stage therapies for cancer and other inflammatory diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Flame Biosciences company profile →
Apogee Therapeutics Logo

Apogee Therapeutics

HQ: United States Website
  • Description: Provider of antibody therapeutics for immunological and inflammatory disorders, including APG777 targeting IL-13 for atopic dermatitis, APG808 targeting IL-4Rα for chronic obstructive pulmonary disease, APG990 targeting OX40L for atopic dermatitis (preclinical), and APG222 dual-inhibiting OX40L and IL-13 for atopic dermatitis; designed for extended half-life and potentially less frequent dosing.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Apogee Therapeutics company profile →
Epirus Biopharma Logo

Epirus Biopharma

HQ: United States Website
  • Description: Provider of biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Epirus Biopharma company profile →
Pathios Therapeutics Logo

Pathios Therapeutics

HQ: United Kingdom Website
  • Description: Provider of small molecule GPR65 inhibitors to develop therapies for autoimmune diseases and cancer, targeting the pH-sensing GPCR GPR65 to counteract immunosuppressive polarization of immune cells. Offerings include PTT-4256, an orally bioavailable, highly potent and selective GPR65 inhibitor for cancer, and CNS-optimized GPR65 inhibitors for malignant brain tumors.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Pathios Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Biotheryx

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Biotheryx

2.2 - Growth funds investing in similar companies to Biotheryx

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Biotheryx

4.2 - Public trading comparable groups for Biotheryx

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Biotheryx

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Biotheryx

What does Biotheryx do?

Biotheryx is a provider of clinical-stage protein degrader therapies, including the PRODEGY platform for targeted protein degradation; PHM molecular glues that use the body’s protein disposal system to selectively degrade disease-causing proteins; BTX-A51, an oral multi-kinase inhibitor for relapsed/refractory AML and high-risk MDS; and a pipeline of first-in-class molecular glue and bifunctional degraders for oncology and inflammatory disorders.

Who are Biotheryx's competitors?

Biotheryx's competitors and similar companies include Anokion, Flame Biosciences, Apogee Therapeutics, Epirus Biopharma, and Pathios Therapeutics.

Where is Biotheryx headquartered?

Biotheryx is headquartered in United States.

How many employees does Biotheryx have?

Biotheryx has 1,000 employees 🔒.

When was Biotheryx founded?

Biotheryx was founded in 2010 🔒.

What sector and industry vertical is Biotheryx in?

Biotheryx is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Biotheryx

Who are the top strategic acquirers in Biotheryx's sector and industry

Top strategic M&A buyers and acquirers in Biotheryx's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Biotheryx?

Top strategic M&A buyers groups and sectors for Biotheryx include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Biotheryx's sector and industry vertical

Which are the top PE firms investing in Biotheryx's sector and industry vertical?

Top PE firms investing in Biotheryx's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Biotheryx's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Biotheryx's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Biotheryx's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Biotheryx include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Biotheryx's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Biotheryx?

The key public trading comparables and valuation benchmarks for Biotheryx include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Biotheryx for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Biotheryx with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Biotheryx's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Biotheryx with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Biotheryx's' sector and industry vertical?

Access recent funding rounds and capital raises in Biotheryx's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Biotheryx